• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Igc Pharma Inc (NY: IGC )

    0.3870 -0.0130 (-3.25%)
    Streaming Delayed Price Updated: 1:11 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Igc Pharma Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
    Via ACCESSWIRE
    BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Receives Two Awards in NIH’s AI PREPARE Challenge
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
    Via ACCESSWIRE
    IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
    IGC Pharma, Inc. (NYSE American: IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge),... 
    Via PRLog
    Topics Artificial Intelligence Intellectual Property Regulatory Compliance
    Exposures Artificial Intelligence Intellectual Property Legal
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1’s Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer’s
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
    From IGC Pharma, Inc.
    Via Business Wire
    InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Advances IGC-AD1 Research to Potentially Deliver ‘Breakthrough Treatment’ in Alzheimer’s Disease
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property Product Safety
    IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
    From IGC Pharma, Inc.
    Via Business Wire
    BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property Regulatory Compliance
    Exposures Artificial Intelligence Intellectual Property Legal
    IGC Announces Results of its 2024 Annual Stockholders Meeting
    From IGC Pharma, Inc.
    Via Business Wire
    InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Preclinical Research Evaluating New Molecule IGC-1C in Treatment of Alzheimer’s Disease
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
    From IGC Pharma, Inc.
    Via Business Wire
    InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) AI-Driven Approach Reveals ‘Promising Opportunity’ for IGC-1A to Be a Potential GLP-1 Agonist
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
    From IGC Pharma
    Via Business Wire
    IGC Stock Earnings: IGC Pharma Beats EPS, Misses Revenue for Q1 2025
    IGC stock results show that IGC Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025. 
    Via InvestorPlace
    BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2025 Financial, Operational Results Report
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In India, Highlights Important Milestones In Alzheimer's Research
    Via Benzinga
    IGC Pharma Reports First Quarter Fiscal 2025 Results
    From IGC Pharma, Inc.
    Via Business Wire
    InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Buy’ Recommendation in AGP’s Analyst Coverage Research Report
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
    From IGC Pharma, Inc.
    Via Business Wire
    BioMedNewsBreaks — IGC Pharma Inc.’s (NYSE American: IGC) TGR-63 Demonstrates Blood-Brain Barrier Permeability in Preliminary Findings
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
    From IGC Pharma, Inc.
    Via Business Wire
    BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Positive Data from TGR-63 Preclinical Studies
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Financial Report for Fiscal Year
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
    From IGC Pharma, Inc.
    Via Business Wire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning! 
    Via InvestorPlace
    IGC Stock Earnings: IGC Pharma Meets EPS, Beats Revenue for Q4 2024
    IGC stock results show that IGC Pharma met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2024. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.